Chimeric antigen receptor (CAR) T-cells have recently provided promising advances as a novel immunotherapeutic approach for cancer treatment especially in B-cell malignancies. CAR T-cell therapy represents an emerging therapeutic option for pancreatic cancer as well. It has shown less success against solid tumors due to heterogeneity of the solid tumor and the specific characteristics of the tumor microenvironment. With development of the new technologies

optimization of CAR structure combined with other therapeutic immunologic adjuvants shows promising results in some clinical trials. This review summarized characteristics of CAR T-cell therapy

its current status in the treatment of pancreatic cancer and the strategies for future treatment.